Patents for A61P 27 - Drugs for disorders of the senses (53,017)
07/2002
07/03/2002CN1357038A Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions
07/03/2002CN1357001A Novel ribose-substituted aromatic amides, method for prodn. and use thereof as medicaments
07/03/2002CN1356911A Method for treatment of fibrosis using antagonist of integrin alpha-4 subunit
07/02/2002US6414148 Produce antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
07/02/2002US6414126 C-aryl glucoside SGLT2 inhibitors and method
07/02/2002US6414032 Anti-infective compositions for treating disordered tissue such as cold sores
07/02/2002US6414022 Cyclopentane(ENE)heptenoic or heptenoic acids and derivatives thereof useful as therapeutic agents
07/02/2002US6414021 Vision defects
07/02/2002US6414011 Central nervous system disorders
07/02/2002US6413996 Diaminocyclobutene-3,4-dione derivatives, their preparation and use
07/02/2002US6413965 Selective cox-2 and an aldose reductase inhibitor; neuropathy, nephropathy, retinopathy and cardiomyopathy; avoiding side effects such as gastric and renal toxicity
07/02/2002US6413963 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
07/02/2002US6413958 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-barr virus; enzyme inhibitors
07/02/2002US6413955 1,8-naphthyridines or 5-thio-1,8-naphthyridines or 5-oxo-1,8-naphthyridines; bone resorption, osteoporosis, vascular rest-enosis, diabetic retinopathy, macular degeneration, angio-genesis, atherosclerosis, inflammatory arthritis, cancer
07/02/2002US6413932 Tek antagonists comprising soluble tek extracellular binding domain
07/02/2002US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor
07/02/2002US6413540 For eyes
07/02/2002US6413527 Nanoemulsion based on alkyl ether citrates and its uses in the cosmetics, dermatological, pharmacological and/or ophthalmological fields
07/02/2002CA2064478C Ophthalmic composition
07/02/2002CA2022119C Substituted aromatic sulfonamides as antiglaucoma agents
06/2002
06/27/2002WO2002050289A1 Methods for the production of multimeric proteins, and related compositions
06/27/2002WO2002050287A2 Multifunctional protease inhibitors and their use in treatment of disease
06/27/2002WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
06/27/2002WO2002050097A2 Anti-allergic complex molecules
06/27/2002WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
06/27/2002WO2002050043A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
06/27/2002WO2002050039A1 Urea and urethane derivatives as integrin inhibitors
06/27/2002WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands
06/27/2002WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor
06/27/2002WO2002050031A1 Indole derivatives
06/27/2002WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt
06/27/2002WO2002049677A1 Lentiviral vector-mediated gene transfer and uses thereof
06/27/2002WO2002049654A1 Shark meat extract
06/27/2002WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
06/27/2002WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
06/27/2002WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
06/27/2002WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat
06/27/2002WO2002049645A1 Therapeutic combination of amlodipine and benazepril
06/27/2002WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
06/27/2002WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
06/27/2002WO2002049615A2 Artificial tear composition containing a combination of three demulcents
06/27/2002WO2002049614A2 Intraocular irrigating solution having improved flow characteristics
06/27/2002WO2002049612A2 Hypertonic ophthalmic irrigation solution adapted for use in lasik surgery
06/27/2002WO2002049574A2 Method for curing child's and adolescent myopia using a spiruline preparation
06/27/2002WO2002022168A3 Vaccine against streptococcus pneumoniae
06/27/2002WO2002022167A3 Vaccine against streptococcus penumoniae
06/27/2002WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
06/27/2002WO2002008231A3 Biologically active macrolides, compositions, and uses thereof
06/27/2002WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx
06/27/2002WO2001074330A3 Method for treating dry eye
06/27/2002WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
06/27/2002US20020082417 Compound for use in the treatment of vision defects and chronic obstructive pulmonary diseases
06/27/2002US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders
06/27/2002US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma
06/27/2002US20020082286 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
06/27/2002US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases
06/27/2002US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
06/27/2002US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
06/27/2002US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds
06/27/2002US20020081659 Nucleic acids, proteins and antibodies
06/27/2002US20020081623 Chemotactic cytokine
06/27/2002US20020081299 Hair cell disorders
06/27/2002US20020081290 Protein kinase homologs
06/27/2002CA2436699A1 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
06/27/2002CA2432879A1 Anti-allergic complex molecules
06/27/2002CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
06/27/2002CA2432638A1 Therapeutic combination of amlodipine and benazepril
06/27/2002CA2432315A1 Methods for the production of multimeric proteins, and related compositions
06/27/2002CA2432301A1 Lentiviral vector-mediated gene transfer and uses thereof
06/27/2002CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat
06/27/2002CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
06/27/2002CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
06/27/2002CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1)
06/27/2002CA2430973A1 Multifunctional protease inhibitors and their use in treatment of disease
06/27/2002CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect
06/27/2002CA2423331A1 Shark meat extract
06/26/2002EP1216707A1 New therapeutic uses of a SMR-1-peptide
06/26/2002EP1216309A2 Methods for targeting rna molecules
06/26/2002EP1216257A1 Compounds for the treatment of ischemia
06/26/2002EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents
06/26/2002EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives
06/26/2002EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216234A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto
06/26/2002EP1216230A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists
06/26/2002EP1216046A2 Novel combination of loteprednol and antihistamines
06/26/2002EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
06/26/2002EP1051155B1 Nasal solutions
06/26/2002EP0820441B1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
06/26/2002CN1355799A 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
06/26/2002CN1355701A Urea substituted imidazoquinolines
06/26/2002CN1355021A Percutaneous medicine of strychnine (toxiferine or securinine) and salt thereof
06/26/2002CN1086590C Eye drops contg. sodium hyaluronate and preparing method thereof
06/25/2002US6410791 Salbutamol; respiratory system disorders
06/25/2002US6410780 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
06/25/2002US6410599 Mixture of benzalkonium chloride, water and isopropanol
06/25/2002US6410591 Vision defects
06/25/2002US6410589 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
06/25/2002US6410583 Prostaglandin antagonist
06/25/2002US6410553 Benzosulfones and related compositions and methods